Literature DB >> 29100618

Incidence and evolution of sepsis-induced cardiomyopathy in a cohort of patients with sepsis and septic shock.

I Narváez1, A Canabal2, C Martín3, M Sánchez2, A Moron4, J Alcalá3, S Giacoman3, M Magro2.   

Abstract

OBJETIVE: The aim of this study was to establish the incidence of septic cardiomyopathy (SM) in patients with sepsis and septic shock, to describe its characteristics and testing its evolution.
DESIGN: Prospective cohort study. PARTICIPANTS: We included 57 consecutive patients admitted to Intensive Care Unit, who met criteria of sepsis and septic shock. PRINCIPAL VARIABLES OF INTEREST: Clinical and biochemical variables were analyzed. An echocardiogram was performed in the first 24hours of admission, determining myocardial function parameters, and if the patients had left ventricular ejection fraction (LVEF)<50%) a second echocardiogram was performed. AMBIT: Intensive medical and surgical Care Service for Adults in University Hospital.
RESULTS: The mean age of the patients was 62,1±16,3 years. 58% were males. 22.8% had left ventricular dysfunction. The mean LVEF in patients with MS was lower than those without SM (34.1±10.6 vs 60.7±6.94%, P<.001), with complete recovery, in survivors, after the acute event (LVEF at discharge 56.1±6.3%, P=.04). Patients with SM had higher levels of procalcitonin (47.1±35.4 vs 18.9±24.5; P=.02) and higher score on the Sequential Organ Failure Assessment (SOFA score) (9.91±3.82 vs 7.47±3.41; P=.037). Mortality was not significantly different between both groups [4 (30.8%) vs 4 (9.1%); P=.07].
CONCLUSIONS: SM is not uncommon and is related to a higher scores on the severity scales. In the survivors, LVEF normalized after the recovery of the acute event.
Copyright © 2017 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

Entities:  

Keywords:  Fracción de eyección del ventrículo izquierdo); Left ventricular ejection fraction; Miocardiopatía séptica; Sepsis; Septic cardiomyopathy sepsis; Septic shock; Shock séptico

Mesh:

Year:  2017        PMID: 29100618     DOI: 10.1016/j.medin.2017.08.008

Source DB:  PubMed          Journal:  Med Intensiva (Engl Ed)        ISSN: 2173-5727


  6 in total

1.  Characterization of critically ill patients with septic shock and sepsis-associated cardiomyopathy using cardiovascular MRI.

Authors:  Fabian Muehlberg; Edyta Blaszczyk; Kerstin Will; Stefan Wilczek; Joerg Brederlau; Jeanette Schulz-Menger
Journal:  ESC Heart Fail       Date:  2022-05-19

2.  Feasibility and discriminatory value of tissue motion annular displacement in sepsis-induced cardiomyopathy: a single-center retrospective observational study.

Authors:  Jieqiong Song; Yao Yao; Shilong Lin; Yizhou He; Duming Zhu; Ming Zhong
Journal:  Crit Care       Date:  2022-07-18       Impact factor: 19.334

3.  Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis.

Authors:  Elisabeth Zechendorf; Caroline E O'Riordan; Lara Stiehler; Natalie Wischmeyer; Fausto Chiazza; Debora Collotta; Bernd Denecke; Sabrina Ernst; Gerhard Müller-Newen; Sina M Coldewey; Bianka Wissuwa; Massimo Collino; Tim-Philipp Simon; Tobias Schuerholz; Christian Stoppe; Gernot Marx; Christoph Thiemermann; Lukas Martin
Journal:  JCI Insight       Date:  2020-04-23

4.  Shikonin Ameliorates LPS-Induced Cardiac Dysfunction by SIRT1-Dependent Inhibition of NLRP3 Inflammasome.

Authors:  Tao Guo; Zhong-Biao Jiang; Zhong-Yi Tong; Yang Zhou; Xiang-Ping Chai; Xian-Zhong Xiao
Journal:  Front Physiol       Date:  2020-10-16       Impact factor: 4.566

5.  Early administration of dobutamine in the treatment of septic shock patients with tumor-a retrospective comparative cohort study.

Authors:  Ya-Fei Wu; Yin Pan; Qiang Tang; Ning Lou; Dao-Feng Wang
Journal:  Ann Transl Med       Date:  2022-08

6.  Lipocalin 10 as a New Prognostic Biomarker in Sepsis-Induced Myocardial Dysfunction and Mortality: A Pilot Study.

Authors:  Lu Wang; Wenjie Xie; Guang Li; Bo Hu; Wei Wu; Liying Zhan; Handong Zou
Journal:  Mediators Inflamm       Date:  2021-05-22       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.